Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 6, 2009, Pages 452-461

  Romero Perez, Diego ^a   Agrawal, Arpita ^b   Jacobsen, Jennifer ^b   Yan, Yilong ^b   Thomas, Robert ^a   Cohen, Seth ^b   Villarreal, Francisco ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Collagen; Extracellular matrix; Infarction; Proteases; Stunning

Indexed keywords

CGS 27023A; FIBRILLAR COLLAGEN; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; PD 166793; PY 2; PYRIDONE DERIVATIVE; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; COCULTURE; COLLAGEN DISEASE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; EX VIVO STUDY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PERFUSION; HEART PROTECTION; HEART RATE; HEART VENTRICLE; ISOLATED HEART; MALE; MUSCLE INJURY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STUNNED HEART MUSCLE;

ANIMALS; CORONARY CIRCULATION; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASES; MYOCARDIAL CONTRACTION; MYOCARDIAL STUNNING; OLIGOPEPTIDES; PYRAZINES; PYRIDONES; PYRONES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SULFONAMIDES;

EID: 68249093940     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a6aa83     Document Type: Article

References (56)

1. Day SM, Westfall MV, Fomicheva EV, et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med. 2006;12:181-189.
2. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury. A new intracellular target for matrix metalloproteinase-2. Circulation. 2005;112: 544-552.
3. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol. 2007; 152:189-205. (Pubitemid 47517601)
4. Rork TH, Hadzimichalis NM, Kappil MA, et al. Acetaminophen attenuates peroxynitrite-activated matrix metalloproteinase-2-mediated troponin I cleavage in the isolated guinea pig myocardium. J Mol Cell Cardiol. 2006;40:553-561.
5. Sung MM, Schulz CG, Wang W, et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein a-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol. 2007;43:429-436. (Pubitemid 47451426)
6. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-242. (Pubitemid 46272129)
7. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
8. Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart Fail Rev. 2004;9:7-19. (Pubitemid 38196073)
9. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210.
10. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med. 2002;12:97-101. (Pubitemid 34462178)
11. Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular disease. Nat Rev Drug Discov. 2007;6:480-498. (Pubitemid 47064570)
12. Kaludercic N, Lindsey ML, Tavazzi B, et al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. 2008;26:24-37.
13. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007;13:333-346. (Pubitemid 46085282)
14. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007;22:1-9.
15. Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol. 2001;8:188-196. (Pubitemid 32396734)
16. Singh RB, Dandekar SP, Elimban V, et al. Role of proteases in the pathophysiology of cardiac disease. Mol Cell Biochem. 2004;263:241-256. (Pubitemid 39256162)
17. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9:63-79. (Pubitemid 38202142)
18. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem. 1997;40: 2525-2532.
19. Jacobsen FE, Lewis JA, Cohen SM. The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem. 2007;2:152-171.
20. Agrawal A, Romero-Perez D, Jacobsen JA, et al. Zinc-binding groups modulate selective inhibition of MMPs. Chem Med Chem. 2008;3: 812-820.
21. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2005;69:677-687.
22. Schafers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004; 109:2554-2559. (Pubitemid 38720556)
23. Puerta DT, Griffin MO, Lewis JA, et al. Heterocyclic, zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem. 2006;11:131-138.
24. Tiwari M, Hemalatha T, Ganesan K, et al. Myocardial ischemia and reperfusion injury in rats: lysosomal hydrolases and matrix metalloproteinases mediated cellular damage. Mol Cell Biochem. 2008;312:81-91.
25. Palmer BS, Hadziahmetovic M, Veci T, et al. Global ischemic duration and reperfusion function in the isolated perfused rat heart. Resuscitation. 2004;62:97-106. (Pubitemid 38916597)
26. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609-634. (Pubitemid 29210931)
27. Kloner RA, Bolli R, Marban E, et al. Medical and cellular implications of stunning, hibernation, and preconditioning. Circulation. 1998;97: 1848-1867. (Pubitemid 28213629)
28. Hansen PR. Myocardial reperfusion injury: experimental evidence and clinical relevance. Eur Heart J. 1995;16:734-740.
29. Grund F, Treiman C, Ilebekk A. How to discriminate between hibernating and stunned myocardium. J Cardiovasc Surg. 2006;47:323-328. (Pubitemid 44043969)
30. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999;68:1905-1912.
31. Villarreal FJ, Kim NN, Ungab GD, et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 1993;88: 2849-2861. (Pubitemid 23360212)
32. Wang GY, Bergman MR, Nguyen AP, et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res. 2006;69:688-696.
33. Go K, Horikawa Y, Garcia R, et al. Fluorescent method for detection of cleaved collagens using O-phthaldialdehyde (OPA). J Biochem Biophys Methods. 2008;70:878-882.
34. Li H, Simon H, Bocan TM, et al. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res. 2000;46:298-306. (Pubitemid 30204602)
35. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87:1285-1342. (Pubitemid 350041472)
36. Roztocil E, Nicholl SM, Davies MG. Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent. Surgery. 2008;144:245-251.
37. Housenloy DJ, Yellon DM. Reperfusion injury salvage kinase signaling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217-234.
38. Housenloy DJ, Yellon DM. Clinical translation of cardioprotective strategies: report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection. Basic Res Cardiol. 2008;103:493-500.
39. Zhang YM, Fan X, Chakaravarty D, et al. 1-hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke. Bioorg Med Chem Lett. 2008;18:409-413.
40. Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted heart. Cardiovasc Res. 2000;46:307-315. (Pubitemid 30204603)
41. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573. (Pubitemid 43139720)
42. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004;20:419-432.
43. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104:1899-1904. (Pubitemid 32983231)
44. Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;290:H232-H239.
45. Cheung P, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000; 101:1833-1839. (Pubitemid 30213106)
46. Lalu MM, Pasini E, Schulze CJ, et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J. 2005; 26:27-35. (Pubitemid 40221120)
47. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543-1549. (Pubitemid 35050883)
48. Fert-Bober J, Leon H, Sawicka J, et al. Inhibiting matrix metalloproteinase- 2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol. 2008;103: 431-443.
49. Swann K, Berger J, Sprague SM, et al. Peripheral thermal injury causes blood-brain barrier dysfunction and matrix metalloproteinase (MMP) expression in rat. Brain Res. 2007;1129:26-33. (Pubitemid 46048776)
50. Vishnubhotla R, Sun S, Hug J, et al. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest. 2007;87:1149-1158. (Pubitemid 47609026)
51. Ferrari R, Guardigli G, Mele D, et al. Oxidative stress during myocardial ischemia and heart failure. Curr Pharm Des. 2004;10:1699-1711. (Pubitemid 38559780)
52. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587-596.
53. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol. 2008;19:2-13.
54. Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 2000;41:613-627. (Pubitemid 30671825)
55. Skrzypiec-Spring M, Grotthus B, Szelag A, et al. Isolated heart perfusion according to Langendorff-still viable in the new millennium. J Pharmacol Toxicol Methods. 2007;55:113-126. (Pubitemid 46227990)
56. Ytrehus K. The ischemic heart-experimental models. Pharmacol Res. 2000;42:193-203.